This Strategic Partnership Will Accelerate Business Growth in Saudi Arabia and the MENA Region
AMMAN, Jordan and RIYADH, Saudi ArabiaMay 19, 2026 /PRNewswire/ — MS Pharma today announced that Olayan Financing Company (OFC) has completed a minority equity investment in the company. This partnership injects strategic depth into MS Pharma’s next phase of growth, underscoring its commitment to innovation, regional expansion, and long-term value creation. The move also marks the beginning of a long-term partnership between OFC and MS Pharma’s existing majority shareholder, whose leadership and excellence in the pharmaceutical sector have been recognized for decades.
The signing ceremony marks a new phase of collaboration between MS Pharma and Olayan Financing Company.
The transaction involves MS Pharma issuing new shares in exchange for a substantial cash investment from OFC, granting OFC a minority stake in the company.
This investment further strengthens MS Pharma’s financial position and operational flexibility, providing robust support for advancing its ambitious growth strategy in the Middle East and North Africa region. It will also help expand its biosimilar product portfolio, enhance manufacturing capabilities, and bolster supply chain resilience, thereby better serving patients, healthcare providers, and partners across the MENA region.
Ghiath Sukhtian, Chairman of MS Pharma, commented on the new partnership: “We are delighted and warmly welcome OFC as a partner in our company. Their global operational and investment expertise, coupled with their deep roots in Saudi Arabia, will bring significant value to MS Pharma and benefit all stakeholders. This investment reflects the exceptional quality and dedication of the talent within our organization. Their leadership and consistent execution have been key to MS Pharma’s growth to where it is today.”
Kalle Kaend, CEO of MS Pharma, added: “This investment comes at an exciting turning point in MS Pharma’s journey. It will enable us to deepen our biologics expertise, expand our market presence in Saudi Arabia and the broader MENA region, and accelerate biosimilar growth. We look forward to leveraging OFC’s experience and established network in Saudi Arabia to achieve our ambitious goals, while continuing to build a high-performance organization that creates long-term value for patients, partners, and employees.”
Nabeel Al-Amudi, CEO of Olayan Financing Company, stated: “MS Pharma has established itself as a leading regional pharmaceutical platform with strong capabilities in generics and biologics. We are pleased to partner with the company at this stage of its development and look forward to supporting its continued expansion in Saudi Arabia and the MENA region, which aligns closely with our long-term investment philosophy.”
This partnership builds on MS Pharma’s leadership in biosimilars, particularly in Saudi Arabia. Its biologics manufacturing facility was the first in the Kingdom to receive SFDA GMP certification for biologics production. This year, the company also plans to become the first supplier in the Saudi market to locally produce biologics. These milestones reinforce the company’s commitment to localization under the Saudi National Biotechnology Strategy and Vision 2030 framework. By expanding access to high-quality biologic therapies across the region and working closely with regional and international health authorities, MS Pharma remains dedicated to the highest standards of regulatory excellence and quality.
MS Pharma also aims to deepen collaboration with global development and licensing partners, leveraging its manufacturing capabilities to support product exports to global markets.
About MS Pharma
MS Pharma is a leading regional pharmaceutical company in the Middle East and North Africa, focused on the development, production, and distribution of a broad portfolio of generics and biologic therapies. Positioned for rapid growth, the company operates five manufacturing facilities in Jordan, Algeria, and Saudi Arabia, including a newly established biologics plant, serving the broader MENA market.
Headquartered in Amman, Jordan, with a management office in Zug, Switzerland, MS Pharma employs over 2,000 people across 12 countries and regions, dedicated to improving patient access to high-quality, affordable medicines.
For more information, please visit www.mspharma.com.
About Olayan Financing Company (OFC)
The Olayan Group was founded in 1947 by its founder, Suliman Saleh Olayan, who established the predecessor company. The enterprise has since evolved and operates under Olayan Financing Company (OFC). As a leading multinational enterprise, OFC holds a diversified business and investment portfolio comprising over 32 companies, with global investments spanning markets in Saudi Arabia, the Middle East, North Africa, Turkey, and India. As a long-term strategic investor, OFC’s investments encompass public equities, private equity, strategic partnerships, and real estate assets, as well as the portfolio of its primary investment, Olayan Saudi Holding Company. The latter operates across five sectors, underpinned by numerous long-standing partnerships spanning decades. OFC boasts a diverse workforce of over 14,500 professionals from more than 60 countries and regions. In line with its commitment to creating long-term positive impact for society, OFC’s philanthropic arm, the Suliman S. Olayan Foundation (SSOF), supports a wide range of initiatives in education, healthcare, and community welfare. As a Saudi enterprise, OFC actively contributes to the economic diversification, local content, talent development, and circular economy goals of Vision 2030.
For more information, please visit www.ofc.com.
Officials from MS Pharma and Olayan Financing Company during the signing ceremony announcing OFC’s partnership with MS Pharma.